Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Second generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs

Saturday, June 1, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the advancements in second generation HBV siRNAs, highlighting their improved profiles compared to ALG-125755 and other clinical stage siRNAs. These novel chemistries may offer enhanced efficacy in treating chronic HBV infections. The findings suggest a promising direction for future therapeutic developments in this area.
Price reaction · baseline $14.75 (2024-05-31 close) · 6 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
+4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Second generation HBV siRNAs show improved profiles.
  • Novel chemistries may enhance treatment efficacy.
  • Comparison with ALG-125755 indicates potential advancements.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What are second generation HBV siRNAs?

Second generation HBV siRNAs are novel therapeutic agents designed to improve treatment efficacy for chronic HBV infections.

How do these siRNAs compare to ALG-125755?

They demonstrate improved profiles compared to ALG-125755 and other clinical stage siRNAs.

What is the significance of novel chemistries?

Novel chemistries in siRNAs may enhance their effectiveness in targeting HBV.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare HBV siRNAs chronic infection clinical stage
Last updated: Jun 1, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →